Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH
Want to see AUPH full AI Analyst Report?
AUPH Stock Chart & Stats
$16.05
$0.10(1.19%)
At close: 4:00 PM EST
$16.05
$0.10(1.19%)
Day’s Range― - ―
52-Week Range$7.29 - $16.88
Previous CloseN/A
Volume460.34K
Average Volume (3M)1.07M
Market Cap
$2.10B
Enterprise Value$2.13B
Total Cash (Recent Filing)$398.00M
Total Debt (Recent Filing)$74.81M
Price to Earnings (P/E)2.5
Beta0.46
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.14
Shares Outstanding132,970,980
10 Day Avg. Volume972,535
30 Day Avg. Volume1,065,605
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.69
Price to Sales (P/S)7.57
P/FCF Ratio15.83
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue7.52
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda14.95
Forecast
1Y Price Target
$16.00Price Target Upside-0.31% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)0.94
Revenue Forecast (FY)$326.80M
Bulls Say, Bears Say
Bulls Say
Acquisition TermsAcquisition brings a novel autoimmune drug into the portfolio at a near-net minimal cash outlay because the target had a strong cash balance and includes contingent value payments that align future payouts with development and cash milestones.
Clinical Pipeline SignalsProof-of-concept efficacy for the acquired autoimmune asset and strong early clinical reductions in immunoglobulins for the aritinercept program support meaningful pipeline upside if safety and registrational strategies are clarified, with once-monthly dosing potentially enhancing competitive positioning.
Guideline-driven Commercial MomentumLupkynis sales are strengthening as updated lupus nephritis and rheumatology guidelines encourage proactive proteinuria screening and favor calcineurin inhibitors, increasing new patient starts, hospital use, and treatment persistence.
Bears Say
Intellectual Property RiskMultiple generic challenges to the company's key dosing patent and ongoing patent litigation threaten long-term exclusivity, risking reduced future sales and increased legal and defense costs.
Regulatory UncertaintyUnresolved alignment with regulators on registrational trial design and a cancelled regulatory meeting introduce uncertainty around the approval pathway, potentially forcing strategic changes and cost-conserving measures.
Safety ConcernsFatal events reported in a clinical trial raise serious safety concerns that create material clinical and regulatory risk and could delay or halt development for the affected program.
Aurinia Pharmaceuticals News
AUPH FAQ
What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $7.29 and its highest was $16.88 in the past 12 months.
What is Aurinia Pharmaceuticals’s market cap?
Aurinia Pharmaceuticals’s market cap is $2.10B.
When is Aurinia Pharmaceuticals’s upcoming earnings report date?
Aurinia Pharmaceuticals’s upcoming earnings report date is Jul 30, 2026 which is in 85 days.
How were Aurinia Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Aurinia Pharmaceuticals overvalued?
According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Overvalued.
Does Aurinia Pharmaceuticals pay dividends?
Aurinia Pharmaceuticals does not currently pay dividends.
What is Aurinia Pharmaceuticals’s EPS estimate?
Aurinia Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aurinia Pharmaceuticals have?
Aurinia Pharmaceuticals has 132,970,980 shares outstanding.
What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
Currently, no hedge funds are holding shares in AUPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aurinia Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (-0.31% Downside)
$16.00 (-0.31% Downside)
Blogger Sentiment
Bullish
AUPH Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.09%
12-Months-Change
Fundamentals
Return on Equity
70.37%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
AUPH Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.View all AUPH earnings summariesAUPH Revenue Breakdown
90.00% U.S.
10.00% Japan
AUPH Stock 12 Month Forecast
Average Price Target
$16.00
▼(-0.31% Downside)
Technical Analysis
Ownership Overview
11.26% Insiders
4.47% Mutual Funds
1.20% Other Institutional Investors
76.09% Public Companies and
Individual Investors